- Home
- Equipment
- usa oklahoma
- drug conjugates
Refine by
Applications
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Affilin - Precision Targeting Technology for Protein Drug Conjugates
- Affilin - Precision Targeting Technology for Radio Conjugates
- Affilin - Precision Targeting Technology for Cellular Therapies
- Affilin - Precision Targeting Technology for Multispecific Ligands
Drug Conjugates Equipment & Supplies In Usa Oklahoma
69 equipment items found
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow, and ...
by:Sword Diagnostics, Inc. based inCarmel, INDIANA (USA)
Sword scientists will use our cell-based assay development expertise to develop a customized method to corroborate the binding specificity of your antibody-drug conjugate (ADC). Our understanding of the molecular basis of cellular growth, proliferation, and differentiation is continually evolving as the genes, proteins, and biochemical pathways critical to these ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. ...
by:Sutro Biopharma Inc. based inSouth San Francisco, CALIFORNIA (USA)
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and AbbVie are co-developing CX-2029, a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy. CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride inhibits topoisomerase IIwith an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces ...
Premium
Manufactured by:AB Sciex LLC based inFramingham, MASSACHUSETTS (USA)
Biotransformation studies are necessary for both small and large molecule therapeutics. From fast and efficient metabolic stability and soft spot analysis to in-depth, comprehensive identification of metabolites and catabolites in a sample, SCIEX offers an integrated solution to give you confident answers ...
Manufactured by:Epitope Diagnostics, Inc. (EDI) based inSan Diego, CALIFORNIA (USA)
This anti-MMAE monoclonal antibody is designed for use in an ELISA environment. It is the primary antibody used in the Epitope Diagnostics Intact MMAE Antibody-Drug Conjugate ELISA Kit. ...
Manufactured by:Navigo Proteins GmbH based inHalle, GERMANY
Navigo Proteins’ Precision Targeting unit leverages its protein engineering expertise to create proprietary Affilin® molecules, harnessed to create optimized, next generation biopharmaceutical drugs in numerous fields of use. Navigo Proteins’ Affilin® platform benefits from the inherent engineerability, stability, safety, and ease of manufacturability. Our ...
Manufactured by:Epitope Diagnostics, Inc. (EDI) based inSan Diego, CALIFORNIA (USA)
This anti-MMAF monoclonal antibody is designed for use in an ELISA environment. It is the primary antibody used in the Epitope Diagnostics Intact MMAF Antibody-Drug Conjugate ELISA Kit. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab ...
Manufactured by:Context Therapeutics Inc. based inPhiladelphia, PENNSYLVANIA (USA)
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many solid tumor types, ...